PACS 2025 presentation: 29% revenue surge, 81% EBITDA jump

PACS Group Inc., a skilled nursing and senior living operator, unveiled its 2025 earnings presentation on February 26, 2026, showcasing exceptional financial performance that drove its stock up 6% in aftermarket trading to $40.02, reflecting investor confidence in the company's 29% revenue surge and 81% EBITDA jump achieved through its consolidation strategy in the fragmented post-acute care market. The company reported full-year 2025 revenue of $5.29 billion, representing a significant increase from 2024's $4.09 billion, while Adjusted EBITDA surged to $505.0 million, demonstrating substantial margin expansion as operational improvements and facility maturation drove profitability. With operations spanning 321 facilities across 17 states serving over 31,700 patients daily, PACS has delivered a remarkable 215% return over the past year, highlighting the effectiveness of its acquisition-driven expansion model in the highly fragmented healthcare market. The company's "locally-led, centrally-supported" operational approach has yielded impressive quality improvements, with mature facilities achieving a 94.9% occupancy rate significantly outperforming industry benchmarks. PACS facilities have seen a 4.2x increase in 4- and 5-star CMS Quality Measure ratings, with mature facilities averaging 4.4 stars. These improvements translate directly to financial benefits, as facilities demonstrate consistent improvement across key metrics as they mature under the company's operating model, with occupancy rising from 81.1% in new facilities to 94.9% in mature ones, and revenue per patient day increasing by approximately 20%. Looking ahead, PACS expects continued but more moderate growth in 2026, projecting revenue of $5.65 billion to $5.75 billion (approximately 8% growth) and Adjusted EBITDA of $555 million to $575 million (about 12% above 2025 levels). The company maintains substantial financial flexibility with a net leverage ratio of just 0.3x and over $600 million in cash and available liquidity, positioning it well to pursue further acquisitions in the skilled nursing market where the top 10 providers control only 11% of approximately 15,000 facilities nationwide. Wall Street analysts maintain a strong buy consensus rating of 1.4, with price targets ranging from $40 to $48, reflecting continued confidence in PACS's strategic positioning and execution capabilities despite the stock trading above its current fair value.